ArticleCancer medicine2026
Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular Carcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Discordant Antitumor Efficacy with Compromised Survival in High-Risk Unresectable Hepatocellular Carcinoma.Cancers · 2026Article
- Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular Carcinoma.Cancer medicine · 2026Article
- Efficacy of Lenvatinib versus Bevacizumab in Triple Therapy with Immune Checkpoint Inhibitors and Interventional Therapy for Hepatocellular Carcinoma with Macrovascular Invasion: A Multi-Center Real-World Retrospective Study.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtezolizumab plus bevacizumab (Atez/Bev) has become the standard first-line therapy for advanced hepatocellular carcinoma (HCC), but optimal second-line strategies remain unclear. This multicenter retrospective study compared survival outcomes and tumor control among first-line regimens and evaluated post-progression efficacy.
methodsWe retrospectively analyzed 1542 patients with advanced HCC who received sorafenib (SOR), lenvatinib (LEN), or Atez/Bev between 2009 and 2022. The main cohort (n = 612) excluded patients who underwent concomitant or inter-line locoregional therapy or entered clinical trials after first-line treatment. Overall survival (OS), progression-free survival (PFS), post-progression survival (PPS), duration of disease control (DDC), and duration of response (DOR) were estimated by Kaplan-Meier analysis and compared by the log-rank test. The impact of disease control and objective response on OS was assessed using time-dependent Cox models.
resultsMedian OS was 15.4 months for SOR, 13.1 for LEN, and 20.6 for Atez/Bev (p = 0.002); Median PFS was 3.5, 5.7, and 7.5 months, respectively (p < 0.001); and median PPS was 10.8, 6.4, and 9.0 months, respectively (p = 0.049). Atez/Bev achieved the longest DDC (8.5 months) and DOR (22.1 months). Disease control and objective response were associated with improved OS (HR: 0.51/0.42 for SOR, 0.54/0.62 for LEN, 0.34/0.35 for Atez/Bev). After progression, median second-line PFS was 5.5 months for SOR, 2.5 for LEN, and 3.0 for Atez/Bev (p = 0.001).
conclusionAtez/Bev provided superior survival and durable tumor control; however, post-progression outcomes remained unsatisfactory, underscoring the need for improved second-line approaches after Atez/Bev failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.